Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma

BACKGROUNDAppendix adenocarcinomas (AAs) are rare tumours that often present late, with a propensity for peritoneal metastases (PMs). This study aimed to evaluate outcomes of AA patients undergoing cytoreductive surgery (CRS) with curative intent and determine the role of systemic chemotherapy.MATER...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESMO open 2023-10, Vol.8 (5), p.101619-101619, Article 101619
Hauptverfasser: Strach, M.C., Chakrabarty, B., Nagaraju, R.T., Mullamitha, S., Braun, M., O’Dwyer, S.T., Aziz, O., Barriuso, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 101619
container_issue 5
container_start_page 101619
container_title ESMO open
container_volume 8
creator Strach, M.C.
Chakrabarty, B.
Nagaraju, R.T.
Mullamitha, S.
Braun, M.
O’Dwyer, S.T.
Aziz, O.
Barriuso, J.
description BACKGROUNDAppendix adenocarcinomas (AAs) are rare tumours that often present late, with a propensity for peritoneal metastases (PMs). This study aimed to evaluate outcomes of AA patients undergoing cytoreductive surgery (CRS) with curative intent and determine the role of systemic chemotherapy.MATERIALS AND METHODSData were collected from a prospective database and classified according to World Health Organization (WHO) 2019 classification. Tumour clearance from CRS was described using a completeness of cytoreduction (CC) score ranging from 0 [no residual disease (RD)] to 3 (>2.5 cm RD). Patients with CC0-2 CRS received hyperthermic intraperitoneal chemotherapy (HIPEC). Systemic chemotherapy was categorised as 'prior' (>6 months before), 'neoadjuvant' (
doi_str_mv 10.1016/j.esmoop.2023.101619
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10619141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2857836980</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-9e260f1ce761d7044ce076f9a354d2a2b131e65d677a5188de2aa08c5df4fd2a3</originalsourceid><addsrcrecordid>eNpVkc1LAzEQxYMoWtT_wEOOXlrzsZvsnkTqJwheFI9hTGZtym6yJtti_3tXW0RPM7z3eAPzI-SMsxlnXF0sZ5i7GPuZYEL-SLzeIxPBynqqmaj3_-xH5DTnJWOM62IU1SE5klqJktdyQl6vsfHBh3cKNMUWaRMTzZs8YOcttQvs4rDABP2G-kDbaKGlEBwFt4ZgcVz6HoPzn6OCYbST9SF2cEIOGmgznu7mMXm5vXme308fn-4e5lePUysrNUxrFIo13KJW3GlWFBaZVk0NsiycAPHGJUdVOqU1lLyqHAoAVtnSNUUzBuQxudz29qu3Dp3FMCRoTZ98B2ljInjz3wl-Yd7j2nA2vowXfGw43zWk-LHCPJjOZ4ttCwHjKhtRlbqSqq7YGC22UZtizgmb3zucmW8IZmm2XMw3F7PlIr8AyCODRw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857836980</pqid></control><display><type>article</type><title>Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Strach, M.C. ; Chakrabarty, B. ; Nagaraju, R.T. ; Mullamitha, S. ; Braun, M. ; O’Dwyer, S.T. ; Aziz, O. ; Barriuso, J.</creator><creatorcontrib>Strach, M.C. ; Chakrabarty, B. ; Nagaraju, R.T. ; Mullamitha, S. ; Braun, M. ; O’Dwyer, S.T. ; Aziz, O. ; Barriuso, J.</creatorcontrib><description>BACKGROUNDAppendix adenocarcinomas (AAs) are rare tumours that often present late, with a propensity for peritoneal metastases (PMs). This study aimed to evaluate outcomes of AA patients undergoing cytoreductive surgery (CRS) with curative intent and determine the role of systemic chemotherapy.MATERIALS AND METHODSData were collected from a prospective database and classified according to World Health Organization (WHO) 2019 classification. Tumour clearance from CRS was described using a completeness of cytoreduction (CC) score ranging from 0 [no residual disease (RD)] to 3 (&gt;2.5 cm RD). Patients with CC0-2 CRS received hyperthermic intraperitoneal chemotherapy (HIPEC). Systemic chemotherapy was categorised as 'prior' (&gt;6 months before), 'neoadjuvant' (&lt;6 months before), 'adjuvant' (&lt;6 months after CC0-1 CRS) or 'palliative' (after CC2-3 CRS). Analyses used Kaplan-Meier and Cox regression methods.RESULTSBetween January 2005 and August 2021, 216 AA patients were identified for inclusion. Median age was 59 years (21-81 years). CRS/HIPEC was carried out in 182 (84%) patients, of whom 164/182 (76%) had mitomycin C HIPEC. CC0-1 was achieved in 172 (80%) patients. Systemic chemotherapy was given to 97 (45%) patients from the whole cohort and to 37/46 (80%) patients with positive nodes. Median overall survival (OS) was 122 months (95% confidence interval 61-182 months). After multivariate analysis, patients with acellular and lower-grade PM had similar OS to those with localised (M0) disease (P = 0.59 and P = 0.19). For patients with positive nodes, systemic chemotherapy was associated with reduced risk of death compared to no chemotherapy (P &lt; 0.0019).CONCLUSIONThis study identifies AA patients with positive lymph nodes derive the most benefit from systemic chemotherapy. We confirm the prognostic importance of stage and peritoneal grade, with excellent outcomes in patients with acellular mucin and lower-grade PM.</description><identifier>ISSN: 2059-7029</identifier><identifier>EISSN: 2059-7029</identifier><identifier>DOI: 10.1016/j.esmoop.2023.101619</identifier><identifier>PMID: 37625193</identifier><language>eng</language><publisher>Elsevier</publisher><subject>Original Research</subject><ispartof>ESMO open, 2023-10, Vol.8 (5), p.101619-101619, Article 101619</ispartof><rights>2023 The Authors 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-9e260f1ce761d7044ce076f9a354d2a2b131e65d677a5188de2aa08c5df4fd2a3</citedby><cites>FETCH-LOGICAL-c386t-9e260f1ce761d7044ce076f9a354d2a2b131e65d677a5188de2aa08c5df4fd2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619141/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619141/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Strach, M.C.</creatorcontrib><creatorcontrib>Chakrabarty, B.</creatorcontrib><creatorcontrib>Nagaraju, R.T.</creatorcontrib><creatorcontrib>Mullamitha, S.</creatorcontrib><creatorcontrib>Braun, M.</creatorcontrib><creatorcontrib>O’Dwyer, S.T.</creatorcontrib><creatorcontrib>Aziz, O.</creatorcontrib><creatorcontrib>Barriuso, J.</creatorcontrib><title>Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma</title><title>ESMO open</title><description>BACKGROUNDAppendix adenocarcinomas (AAs) are rare tumours that often present late, with a propensity for peritoneal metastases (PMs). This study aimed to evaluate outcomes of AA patients undergoing cytoreductive surgery (CRS) with curative intent and determine the role of systemic chemotherapy.MATERIALS AND METHODSData were collected from a prospective database and classified according to World Health Organization (WHO) 2019 classification. Tumour clearance from CRS was described using a completeness of cytoreduction (CC) score ranging from 0 [no residual disease (RD)] to 3 (&gt;2.5 cm RD). Patients with CC0-2 CRS received hyperthermic intraperitoneal chemotherapy (HIPEC). Systemic chemotherapy was categorised as 'prior' (&gt;6 months before), 'neoadjuvant' (&lt;6 months before), 'adjuvant' (&lt;6 months after CC0-1 CRS) or 'palliative' (after CC2-3 CRS). Analyses used Kaplan-Meier and Cox regression methods.RESULTSBetween January 2005 and August 2021, 216 AA patients were identified for inclusion. Median age was 59 years (21-81 years). CRS/HIPEC was carried out in 182 (84%) patients, of whom 164/182 (76%) had mitomycin C HIPEC. CC0-1 was achieved in 172 (80%) patients. Systemic chemotherapy was given to 97 (45%) patients from the whole cohort and to 37/46 (80%) patients with positive nodes. Median overall survival (OS) was 122 months (95% confidence interval 61-182 months). After multivariate analysis, patients with acellular and lower-grade PM had similar OS to those with localised (M0) disease (P = 0.59 and P = 0.19). For patients with positive nodes, systemic chemotherapy was associated with reduced risk of death compared to no chemotherapy (P &lt; 0.0019).CONCLUSIONThis study identifies AA patients with positive lymph nodes derive the most benefit from systemic chemotherapy. We confirm the prognostic importance of stage and peritoneal grade, with excellent outcomes in patients with acellular mucin and lower-grade PM.</description><subject>Original Research</subject><issn>2059-7029</issn><issn>2059-7029</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkc1LAzEQxYMoWtT_wEOOXlrzsZvsnkTqJwheFI9hTGZtym6yJtti_3tXW0RPM7z3eAPzI-SMsxlnXF0sZ5i7GPuZYEL-SLzeIxPBynqqmaj3_-xH5DTnJWOM62IU1SE5klqJktdyQl6vsfHBh3cKNMUWaRMTzZs8YOcttQvs4rDABP2G-kDbaKGlEBwFt4ZgcVz6HoPzn6OCYbST9SF2cEIOGmgznu7mMXm5vXme308fn-4e5lePUysrNUxrFIo13KJW3GlWFBaZVk0NsiycAPHGJUdVOqU1lLyqHAoAVtnSNUUzBuQxudz29qu3Dp3FMCRoTZ98B2ljInjz3wl-Yd7j2nA2vowXfGw43zWk-LHCPJjOZ4ttCwHjKhtRlbqSqq7YGC22UZtizgmb3zucmW8IZmm2XMw3F7PlIr8AyCODRw</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Strach, M.C.</creator><creator>Chakrabarty, B.</creator><creator>Nagaraju, R.T.</creator><creator>Mullamitha, S.</creator><creator>Braun, M.</creator><creator>O’Dwyer, S.T.</creator><creator>Aziz, O.</creator><creator>Barriuso, J.</creator><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20231001</creationdate><title>Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma</title><author>Strach, M.C. ; Chakrabarty, B. ; Nagaraju, R.T. ; Mullamitha, S. ; Braun, M. ; O’Dwyer, S.T. ; Aziz, O. ; Barriuso, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-9e260f1ce761d7044ce076f9a354d2a2b131e65d677a5188de2aa08c5df4fd2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strach, M.C.</creatorcontrib><creatorcontrib>Chakrabarty, B.</creatorcontrib><creatorcontrib>Nagaraju, R.T.</creatorcontrib><creatorcontrib>Mullamitha, S.</creatorcontrib><creatorcontrib>Braun, M.</creatorcontrib><creatorcontrib>O’Dwyer, S.T.</creatorcontrib><creatorcontrib>Aziz, O.</creatorcontrib><creatorcontrib>Barriuso, J.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ESMO open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strach, M.C.</au><au>Chakrabarty, B.</au><au>Nagaraju, R.T.</au><au>Mullamitha, S.</au><au>Braun, M.</au><au>O’Dwyer, S.T.</au><au>Aziz, O.</au><au>Barriuso, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma</atitle><jtitle>ESMO open</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>8</volume><issue>5</issue><spage>101619</spage><epage>101619</epage><pages>101619-101619</pages><artnum>101619</artnum><issn>2059-7029</issn><eissn>2059-7029</eissn><abstract>BACKGROUNDAppendix adenocarcinomas (AAs) are rare tumours that often present late, with a propensity for peritoneal metastases (PMs). This study aimed to evaluate outcomes of AA patients undergoing cytoreductive surgery (CRS) with curative intent and determine the role of systemic chemotherapy.MATERIALS AND METHODSData were collected from a prospective database and classified according to World Health Organization (WHO) 2019 classification. Tumour clearance from CRS was described using a completeness of cytoreduction (CC) score ranging from 0 [no residual disease (RD)] to 3 (&gt;2.5 cm RD). Patients with CC0-2 CRS received hyperthermic intraperitoneal chemotherapy (HIPEC). Systemic chemotherapy was categorised as 'prior' (&gt;6 months before), 'neoadjuvant' (&lt;6 months before), 'adjuvant' (&lt;6 months after CC0-1 CRS) or 'palliative' (after CC2-3 CRS). Analyses used Kaplan-Meier and Cox regression methods.RESULTSBetween January 2005 and August 2021, 216 AA patients were identified for inclusion. Median age was 59 years (21-81 years). CRS/HIPEC was carried out in 182 (84%) patients, of whom 164/182 (76%) had mitomycin C HIPEC. CC0-1 was achieved in 172 (80%) patients. Systemic chemotherapy was given to 97 (45%) patients from the whole cohort and to 37/46 (80%) patients with positive nodes. Median overall survival (OS) was 122 months (95% confidence interval 61-182 months). After multivariate analysis, patients with acellular and lower-grade PM had similar OS to those with localised (M0) disease (P = 0.59 and P = 0.19). For patients with positive nodes, systemic chemotherapy was associated with reduced risk of death compared to no chemotherapy (P &lt; 0.0019).CONCLUSIONThis study identifies AA patients with positive lymph nodes derive the most benefit from systemic chemotherapy. We confirm the prognostic importance of stage and peritoneal grade, with excellent outcomes in patients with acellular mucin and lower-grade PM.</abstract><pub>Elsevier</pub><pmid>37625193</pmid><doi>10.1016/j.esmoop.2023.101619</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2059-7029
ispartof ESMO open, 2023-10, Vol.8 (5), p.101619-101619, Article 101619
issn 2059-7029
2059-7029
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10619141
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original Research
title Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A57%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Defining%20a%20role%20for%20systemic%20chemotherapy%20in%20local%20and%20advanced%20appendix%20adenocarcinoma&rft.jtitle=ESMO%20open&rft.au=Strach,%20M.C.&rft.date=2023-10-01&rft.volume=8&rft.issue=5&rft.spage=101619&rft.epage=101619&rft.pages=101619-101619&rft.artnum=101619&rft.issn=2059-7029&rft.eissn=2059-7029&rft_id=info:doi/10.1016/j.esmoop.2023.101619&rft_dat=%3Cproquest_pubme%3E2857836980%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2857836980&rft_id=info:pmid/37625193&rfr_iscdi=true